These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

67 related items for PubMed ID: 12647551

  • 1. [Interstitial boost and altered fractionation as novel approaches to dose escalation in the radiotherapy of glioblastoma multiforme].
    Mangel L, Julow J, Major T, Hável J, Lövey J, Viola A, Somogyi A, Németh G.
    Orv Hetil; 2003 Feb 02; 144(5):223-9. PubMed ID: 12647551
    [Abstract] [Full Text] [Related]

  • 2. [The possibilities of fractionated external beam repeat irradiation of relapsed primary brain tumours: the first Hungarian experience].
    Mangel L, Sipos L, Fedorcsák I, Viola A, Julow J, Bajcsay A, Németh G, Fodor J.
    Orv Hetil; 2007 Sep 30; 148(39):1843-9. PubMed ID: 17890172
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
    Hulshof MC, Koot RW, Schimmel EC, Dekker F, Bosch DA, González González D.
    Strahlenther Onkol; 2001 Jun 30; 177(6):283-90. PubMed ID: 11446316
    [Abstract] [Full Text] [Related]

  • 4. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.
    Tselis N, Kolotas C, Birn G, Röddiger S, Filipowicz I, Kontova M, Fountzilas G, Selviaridis P, Baltas D, Heyd R, Anagnostopoulos G, Zamboglou N.
    Strahlenther Onkol; 2007 Oct 30; 183(10):563-70. PubMed ID: 17896088
    [Abstract] [Full Text] [Related]

  • 5. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):511-9. PubMed ID: 16168843
    [Abstract] [Full Text] [Related]

  • 6. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
    Roddiger SJ, Kolotas C, Filipowicz I, Kurek R, Kuner RP, Martin T, Baltas D, Rogge B, Kontova M, Hoffmann G, Pollow B, Zamboglou N.
    Strahlenther Onkol; 2006 Jan 01; 182(1):22-9. PubMed ID: 16404517
    [Abstract] [Full Text] [Related]

  • 7. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
    Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B.
    Int J Radiat Oncol Biol Phys; 2007 May 01; 68(1):159-65. PubMed ID: 17331666
    [Abstract] [Full Text] [Related]

  • 8. Radiotherapy of malignant gliomas: results from conventional treatment methods and the prospects of advanced techniques.
    Rubino G, Sacco P, Cerase A, Volterrani L, Sebaste L, Pepi F, Pirtoli L.
    Radiol Med; 2004 May 01; 107(1-2):128-35. PubMed ID: 15031704
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ, Shakespeare TP, Tan LK, Goh BC, Cooper JS.
    Head Neck; 2004 May 01; 26(5):389-95. PubMed ID: 15122654
    [Abstract] [Full Text] [Related]

  • 10. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.
    Radiother Oncol; 2012 Aug 01; 104(2):181-6. PubMed ID: 22853851
    [Abstract] [Full Text] [Related]

  • 11. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
    Pötter R, Knocke TH, Fellner C, Baldass M, Reinthaller A, Kucera H.
    Cancer Radiother; 2000 Aug 01; 4(2):159-72. PubMed ID: 10812362
    [Abstract] [Full Text] [Related]

  • 12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):463-71. PubMed ID: 16168838
    [Abstract] [Full Text] [Related]

  • 13. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C, Nestle U, Ketter R, Kolles H, Gentner SJ, Steudel WI, Schnabel K.
    Radiat Oncol Investig; 1999 Oct 01; 7(1):36-41. PubMed ID: 10030622
    [Abstract] [Full Text] [Related]

  • 14. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.
    Douglas JG, Stelzer KJ, Mankoff DA, Tralins KS, Krohn KA, Muzi M, Silbergeld DL, Rostomily RC, Scharnhorst J, Spence AM.
    Int J Radiat Oncol Biol Phys; 2006 Mar 01; 64(3):886-91. PubMed ID: 16242251
    [Abstract] [Full Text] [Related]

  • 15. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
    Odrazka K, Petera J, Kohlova T, Dolezel M, Vaculikova M, Zouhar M, Malek V, Hobza V, Latr I, Nemecek S, Sercl M, Ryska P, Blaha M, Cermakova E.
    Strahlenther Onkol; 2003 Sep 01; 179(9):615-9. PubMed ID: 14628127
    [Abstract] [Full Text] [Related]

  • 16. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
    Fokdal L, Tanderup K, Nielsen SK, Christensen HK, Røhl L, Pedersen EM, Schønemann NK, Lindegaard JC.
    Radiother Oncol; 2011 Sep 01; 100(3):473-9. PubMed ID: 21924784
    [Abstract] [Full Text] [Related]

  • 17. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T, Jorcano S, Escudé L, Linero D, Rouzaud M, Dubouloz A, Miralbell R.
    Clin Oncol (R Coll Radiol); 2014 Jun 01; 26(6):316-22. PubMed ID: 24667210
    [Abstract] [Full Text] [Related]

  • 18. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
    Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM.
    J Nucl Med; 2002 Dec 01; 43(12):1667-73. PubMed ID: 12468518
    [Abstract] [Full Text] [Related]

  • 19. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
    Morton G, Loblaw A, Cheung P, Szumacher E, Chahal M, Danjoux C, Chung HT, Deabreu A, Mamedov A, Zhang L, Sankreacha R, Vigneault E, Springer C.
    Radiother Oncol; 2011 Sep 01; 100(3):463-7. PubMed ID: 21924511
    [Abstract] [Full Text] [Related]

  • 20. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD, Gagel B, Pinkawa M, Stanzel S, Asadpour B, Eble MJ.
    Strahlenther Onkol; 2007 Dec 01; 183(12):695-702. PubMed ID: 18040615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.